U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Tobacco Products
  3. CTP Newsroom
  4. FDA’s Proposed New Requirements for Tobacco Product Manufacturing Practices - 04/12/2023
  1. CTP Newsroom

Public Hearing | Virtual

Event Title
FDA’s Proposed New Requirements for Tobacco Product Manufacturing Practices
April 12, 2023

Scheduled
Date:
April 12, 2023
Organized By:
Organizer

On this page:

Session Recording

Public Oral Hearing Objective

FDA held a public oral hearing on April 12, 2023, to provide stakeholders with an opportunity to share their comments on the proposed rule: “Requirements for Tobacco Product Manufacturing Practice.”

FDA proposed new requirements for tobacco product manufacturers regarding the manufacture, design, packing, and storage of their products. These proposed requirements would help protect public health by, among other things, minimizing or preventing contamination and limiting additional risks by ensuring product consistency. The public oral hearing allowed FDA to gather additional comments on the proposed rule from stakeholders, including industry, the scientific community, advocacy groups, and the public. 

FDA’s aim was to make this hearing a transparent and inclusive opportunity to hear a range of ideas and perspectives from all interested parties. Groups and organizations were asked to select a single spokesperson to help FDA hear as many different perspectives as possible. No presentation materials or slides were used during the hearing.

Live closed captioning and ASL interpreters  were provided during the listening session. The transcript and recordingare now available and are accessible through the dockets as well as on this page.

This public oral hearing featured the following participants:

  • Opening Moderator 
    • Necola Staples, MBA Supervisory Health Communications Specialist, Office of Health Communications and Education, Center for Tobacco Products (CTP), FDA
  • Presiding Officer 
    • Dr. Brian King, PhD, MPH, Director, CTP, FDA
  • Panelists
    • Mr. Matthew Brenner, J.D., Senior Regulatory Counsel, Office of Regulations, CTP, FDA
    • Mr. Emil Wang, J.D., Rear Admiral, U.S. Public Health Service, Senior Regulatory Counsel and Senior Advisor for Manufacturing and Regulatory Policy, Office of Compliance and Enforcement, CTP, FDA
    • Dr. Dale Slavin, PhD, Supervisory Science Policy Analyst, Branch Director, Science Policy Branch, Office of Science, CTP, FDA
    • Dr. Matthew Walters, PhD, MPH, Commander, U.S. Public Health Service, Deputy Division Director, Division of Product Science, Office of Science, CTP, FDA
    • Ms. Diana Kaneva, Associate Chief Counsel, Office of the Chief Counsel, OC, FDA
    • Mr. Dylan Leischow, M.A., Economist, Office of Regulations, CTP, FDA
    • Dr./Ms./Mr. Cristina McLaughlin (FDA OEA), Office of Economic Analysis, FDA
 
Back to Top